TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2666282

Group type: EXPERIMENTAL
Intervention: Prophylactic endoscopic sclerotherapy
Number of subjects: 87

Group type: COMPARATOR
Intervention: Control group (no sclerotherapy)
Number of subjects: 87
Study: 29487957

Group type: EXPERIMENTAL
Intervention: Parallel pins from metacarpal head through MCP joint to proximal phalanx
Number of subjects: 61

Group type: COMPARATOR
Intervention: Cross pins from the base of the proximal phalanx
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Both methods (parallel pins and cross pins)
Number of subjects: 61
Study: 27369739

Group type: EXPERIMENTAL
Intervention: Extralevator abdominoperineal excision (ELAPE)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Non-extralevator abdominoperineal excision (non-ELAPE)
Number of subjects: 34
Study: 25759106

Group type: EXPERIMENTAL
Intervention: Hydration with isotonic saline (1 ml/kg/h since the beginning of the procedure and for 24 hours after it)
Number of subjects: 408

Group type: COMPARATOR
Intervention: No hydration (NS- group)
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: Hydration with isotonic saline
Number of subjects: 408
Study: 23843932

Group type: EXPERIMENTAL
Intervention: Automated emails with the Wellbeing Course
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Wellbeing Course without automated emails
Number of subjects: 257

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 257
Study: 21734179

Group type: EXPERIMENTAL
Intervention: 4-aminopyridine (4AP) 5 mg 3 times daily
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 19827525

Group type: EXPERIMENTAL
Intervention: Erythrone system evaluation in CCI patients
Number of subjects: 30
Study: 16760508

Group type: EXPERIMENTAL
Intervention: Folic acid (1 mg/d)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 12915826

Group type: COMPARATOR
Intervention: CICU LOS quartile 1
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Hospital LOS quartile
Number of subjects: 155
Study: 10486353

Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg twice daily for 24 months
Number of subjects: 68

Group type: COMPARATOR
Intervention: Ranitidine 150 mg twice daily for 24 months
Number of subjects: 68
Study: 8614905

Group type: EXPERIMENTAL
Intervention: 0.5% metallic mercury in petrolatum
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 0.01% phenyl mercuric acetate in water
Number of subjects: 60

Group type: COMPARATOR
Intervention: Saline or petrolatum (control)
Number of subjects: 60
Study: 2006663

Group type: EXPERIMENTAL
Intervention: Diuretics and methyldopa
Number of subjects: 691

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 691
Study: 7168635

Group type: EXPERIMENTAL
Intervention: Short term prophylaxis with a single intravenous dose of tobramycin and lincomycin
Number of subjects: 30

Group type: COMPARATOR
Intervention: No antibiotic treatment (control group)
Number of subjects: 30
Study: 31352415

Group type: EXPERIMENTAL
Intervention: Postextubation medical therapy (azithromycin 250 mg and budesonide 0.5 mg for 14 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Postextubation medical therapy (azithromycin and inhaled budesonide)
Number of subjects: 0
Study: 28069467

Group type: EXPERIMENTAL
Intervention: 20 mg of pantoprazole twice daily and diet changes for 3 months
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (asymptomatic subjects)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Treatment (pantoprazole and diet changes)
Number of subjects: 44
Study: 26161926

Group type: EXPERIMENTAL
Intervention: Ibrutinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Watch-and-wait (placebo)
Number of subjects: 0
Study: 22955246

Group type: EXPERIMENTAL
Intervention: OROS‐MPH
Number of subjects: 215

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 215
Study: 21498312

Group type: EXPERIMENTAL
Intervention: Body weight-adapted CM injection protocol (0.9 mL CM (370 mg I/mL) per kg during 12 s resulting in a constant injection dose rate of 28 mg I/kg/s)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Fixed dose CM injection protocol (65 mL CM (370 mg I/mL) at 5 mL/s)
Number of subjects: 100
Study: 18184948

Group type: EXPERIMENTAL
Intervention: Rivastigmine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nimodipine (active control)
Number of subjects: 0
Study: 16831185

Group type: EXPERIMENTAL
Intervention: Acellular dermal matrix (ADM) with partial thickness flap
Number of subjects: 15

Group type: COMPARATOR
Intervention: Epithelial abrasion
Number of subjects: 15
Study: 19761076

Group type: EXPERIMENTAL
Intervention: Chemotherapy regimens
Number of subjects: 0
Study: 10925979

Group type: EXPERIMENTAL
Intervention: 500‐mg Rowasa (mesalamine) suppository
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study: 8923784

Group type: EXPERIMENTAL
Intervention: Regimen I: 400 mg of MST-16 combined with 25 mg of VP-16 administered daily
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Regimen II: 400 mg of MST-16 combined with 25 mg of VP-16 administered intermittently (3 days a week or every other day)
Number of subjects: 31
Study: 1376177

Group type: EXPERIMENTAL
Intervention: i.v. polyimmune gammaglobulin (500 mg/kg) within 3 days of transplant with 250 mg/kg at weeks 1, 2, 4, and 6
Number of subjects: 0

Group type: COMPARATOR
Intervention: No prophylaxis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nashville/rabbit antithymocyte serum (N/R‐ATS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Monoclonal anti‐CD‐3 therapy
Number of subjects: 0
Study: 6377851

Group type: EXPERIMENTAL
Intervention: Intramuscular injections of 40 mg of mixed gangliosides for ALS for six months
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Intramuscular injections of 40 mg of mixed gangliosides for diabetic neuropathy for three months
Number of subjects: 40
Study: 30835650

Group type: EXPERIMENTAL
Intervention: Whole Body Vibration (WBV) at 30 Hz
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Static first position demi-plié
Number of subjects: 59
Study: 29140142

Group type: EXPERIMENTAL
Intervention: Caffeinated coffee (0.09 g·kg‐1)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Decaffeinated coffee (0.09 g·kg‐1)
Number of subjects: 13
Study: 27680390

Group type: EXPERIMENTAL
Intervention: 12-week aerobic exercise intervention
Number of subjects: 47
Study: 23553186

Group type: EXPERIMENTAL
Intervention: Evidence-based information
Number of subjects: 1577

Group type: COMPARATOR
Intervention: Standard information
Number of subjects: 1577
Study: 22676647

Group type: EXPERIMENTAL
Intervention: Osteopathic technique
Number of subjects: 38

Group type: COMPARATOR
Intervention: Sham technique
Number of subjects: 38
Study: 20386344

Group type: EXPERIMENTAL
Intervention: E2 alone (transdermal E2 0.72 mg for 2 days)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: E2 + DNG (E2 0.72 mg + DNG 2 mg/d for 1 week)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: E2 + MPA (E2 0.72 mg + MPA 2.5 mg/d for 1 week)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 20
Study: 18245699

Group type: EXPERIMENTAL
Intervention: Off-pump coronary artery grafting
Number of subjects: 124

Group type: COMPARATOR
Intervention: Conventional coronary bypass
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 124
Study: 16345016

Group type: EXPERIMENTAL
Intervention: Active drug
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural psychotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 14602753

Group type: EXPERIMENTAL
Intervention: r-hGH (0.067 mg/kg.d)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 11199863

Group type: EXPERIMENTAL
Intervention: Tumour resection
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (healthy individuals)
Number of subjects: 24
Study: 9408810

Group type: EXPERIMENTAL
Intervention: Olanzapine 10 mg/day or 1 mg/day
Number of subjects: 79
Study: 8329024

Group type: EXPERIMENTAL
Intervention: CB0006 at 0.1 mg/kg
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: CB0006 at 1 mg/kg
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: CB0006 at 5 mg/kg
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group (11 children)
Number of subjects: 41
Study: 4036826

Group type: EXPERIMENTAL
Intervention: Dipyridamole infusion (0.14 mg/kg/min for 4 minutes)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Exercise stress testing (EST)
Number of subjects: 66
Study: 30803743

Group type: EXPERIMENTAL
Intervention: K-wire group (20 patients)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Plate group (20 patients)
Number of subjects: 40
Study: 29538628

Group type: EXPERIMENTAL
Intervention: Metaphor message (the body is a family)
Number of subjects: 168

Group type: COMPARATOR
Intervention: No metaphor message
Number of subjects: 168
Study: 27393268

Group type: EXPERIMENTAL
Intervention: Uterine artery embolization
Number of subjects: 177

Group type: COMPARATOR
Intervention: Hysterectomy
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Uterine artery embolization and Hysterectomy
Number of subjects: 177
Study: 24814231

Group type: EXPERIMENTAL
Intervention: IN dexmedetomidine (1 μg/kg) with midazolam premedication
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: IN fentanyl (2 μg/kg) with midazolam premedication
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: IN dexmedetomidine (1 μg/kg) without premedication
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: IN fentanyl (2 μg/kg) without premedication
Number of subjects: 100

Group type: COMPARATOR
Intervention: No premedication
Number of subjects: 100
Study: 22858558

Group type: EXPERIMENTAL
Intervention: Sunitinib
Number of subjects: 319
Study: 19076177

Group type: EXPERIMENTAL
Intervention: Immediate/early loading of zygomatic implants
Number of subjects: 25

Group type: COMPARATOR
Intervention: Regular implants
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Immediate/early loading protocol
Number of subjects: 25
Study: 18441038

Group type: EXPERIMENTAL
Intervention: Combination therapy (9 minutes of electrical stimulation on the dorsiflexor muscles and 15 minutes of inhibitory Bobath techniques)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Bobath techniques (15 minutes)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Bobath techniques
Number of subjects: 40
Study: 16160622

Group type: EXPERIMENTAL
Intervention: Aripiprazole (initial dose 2 mg/d, titrated to 5, 10, or 15 mg/d)
Number of subjects: 208

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 208
Study: 12969190

Group type: EXPERIMENTAL
Intervention: IFN TIW (5 MU thrice weekly for 8 weeks followed by 3 MU TIW for 40 weeks)
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: IFN QD (5 MU daily for 8 weeks followed by 3 MU QD for 16 weeks followed by 3 MU TIW for 24 weeks)
Number of subjects: 301

Group type: COMPARATOR
Intervention: IFN TIW
Number of subjects: 301

Group type: COMPARATOR
Intervention: IFN QD
Number of subjects: 301
Study: 10397076

Group type: EXPERIMENTAL
Intervention: BCAA treatment (200 ml of BCAA-rich solution daily for 7 days)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Thyrotropin-releasing hormone (TRH; protirelin)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 8025461

Group type: EXPERIMENTAL
Intervention: Allen scores
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Siriraj scores
Number of subjects: 231
Study: 2582726

Group type: EXPERIMENTAL
Intervention: Head-up tilting test
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Carotid baroreceptor stimulation by neck suction
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Prolonged head-up tilting test (up to 1 hour)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Neck suction stimulation
Number of subjects: 67
Study: 780407

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate aerosol at 400 mug per day for 4 weeks
Number of subjects: 93

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 93
Study: 30802725

Group type: EXPERIMENTAL
Intervention: High-dairy condition (4 servings a day of full-fat dairy products + regular diet)
Number of subjects: 60

Group type: COMPARATOR
Intervention: No-dairy condition (plant-based food items + regular diet)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: High-dairy condition
Number of subjects: 60

Group type: COMPARATOR
Intervention: No-dairy condition
Number of subjects: 60
Study: 28577584

Group type: EXPERIMENTAL
Intervention: Immediate Computer-Assisted CIFFTA
Number of subjects: 80
Study: 25700756

Group type: EXPERIMENTAL
Intervention: Balloon aortic valvuloplasty (BAV) within 30 days of randomization
Number of subjects: 179

Group type: COMPARATOR
Intervention: No balloon aortic valvuloplasty (no BAV) within 30 days of randomization
Number of subjects: 179
Study: 23777324

Group type: EXPERIMENTAL
Intervention: Diclofenac epolamine (DHEP) 1.3% medicated plaster
Number of subjects: 384

Group type: COMPARATOR
Intervention: Placebo plaster
Number of subjects: 384
Study: 19633850

Group type: EXPERIMENTAL
Intervention: PI-88 delivered subcutaneously (SC) at doses ranging from 80 to 315 mg
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: PI-88 delivered subcutaneously (SC)
Number of subjects: 76
Study: 18451646

Group type: EXPERIMENTAL
Intervention: Clarithromycin 500 mg once daily for 2 weeks
Number of subjects: 4372

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4372
Study: 17239096

Group type: EXPERIMENTAL
Intervention: Radiofrequency catheter ablation
Number of subjects: 226

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 226
Study: 12792328

Group type: EXPERIMENTAL
Intervention: Positron emission tomography (PET)
Number of subjects: 48
Study: 10993128

Group type: EXPERIMENTAL
Intervention: Sertraline (50-200 mg)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Clomipramine (50-150 mg)
Number of subjects: 166
Study: 9126791

Group type: EXPERIMENTAL
Intervention: Hepatitis G virus infection
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Hepatitis C virus infection
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Coinfection with hepatitis C virus
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Hepatitis C virus genotype 3a
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Hepatitis C virus infection alone
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Hepatitis G virus positive patients
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Human immunodeficiency virus infection
Number of subjects: 117
Study: 1541312

Group type: EXPERIMENTAL
Intervention: Extended release tablets once daily (o.m.)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Extended release tablets twice daily (b.d.)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Plain tablets twice daily (b.d.)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Extended release tablets
Number of subjects: 16
Study: 3157887

Group type: EXPERIMENTAL
Intervention: Mesoglycan
Number of subjects: 0

Group type: COMPARATOR
Intervention: Capillary protective drug derived from rutin
Number of subjects: 0
Study: 30846294

Group type: EXPERIMENTAL
Intervention: Ablative fractional CO2 laser (AFCO2L) treatment
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard scar care
Number of subjects: 20
Study: 30296552

Group type: COMPARATOR
Intervention: 0.9% NaCl
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: SilverSol/H2O2
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: HYBENX
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: QMix 2 in1
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: 6% NaOCl
Number of subjects: 51
Study: 26811679

Group type: EXPERIMENTAL
Intervention: Paliperidone-ER (3-12 mg/day)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study: 24977631

Group type: EXPERIMENTAL
Intervention: HBOC-201
Number of subjects: 160

Group type: COMPARATOR
Intervention: RBC transfusions
Number of subjects: 160
Study: 22553980

Group type: EXPERIMENTAL
Intervention: 10 mg dronabinol
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 20 mg dronabinol
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Dronabinol (10 mg and 20 mg)
Number of subjects: 24
Study: 20441572

Group type: EXPERIMENTAL
Intervention: Diabetes-specific cognitive behavioural therapy adapted for the elderly
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intensified treatment as usual
Number of subjects: 0

Group type: COMPARATOR
Intervention: Guided self-help intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All treatment conditions after 12 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All groups at one-year follow-up
Number of subjects: 0
Study: 17663093

Group type: EXPERIMENTAL
Intervention: Laparoscopic appendectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Open appendectomy
Number of subjects: 0
Study: 16037751

Group type: EXPERIMENTAL
Intervention: Unopposed micronized 17beta-estradiol
Number of subjects: 222

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 222
Study: 12139152

Group type: EXPERIMENTAL
Intervention: Oral vaccine prepared from insect saliva
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (stable vaccine solvent)
Number of subjects: 0
Study: 9923552

Group type: EXPERIMENTAL
Intervention: UFT 300 mg/m2 per day plus LV 90 mg per day in three divided doses every 8 h for 28 days
Number of subjects: 19

Group type: COMPARATOR
Intervention: Oral LV 30 mg plus UFT 200 mg
Number of subjects: 19
Study: 8635038

Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (r‐HuEPO) administered subcutaneously at a dose of 150 U/kg three times per week for 6 weeks; in nonresponders, the dose was doubled for the subsequent 6 weeks.
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (r‐HuEPO)
Number of subjects: 102
Study: 1871856

Group type: EXPERIMENTAL
Intervention: Induction ALG
Number of subjects: 110

Group type: COMPARATOR
Intervention: Continuous IV CyA
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: CyA monotherapy
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: First rejection
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Second rejection
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Third rejection
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Rejections after 30 days
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Rejections after 90 days
Number of subjects: 110
Study: 6352600

Group type: EXPERIMENTAL
Intervention: Azlocillin at 18 g/day for a mean of 13 days
Number of subjects: 42

Group type: COMPARATOR
Intervention: Gentamicin at 180 mg/day for a mean of 11 days
Number of subjects: 42
Study: 30277424

Group type: EXPERIMENTAL
Intervention: Anchored to a four-times-daily treatment regimen
Number of subjects: 100

Group type: COMPARATOR
Intervention: Not anchored
Number of subjects: 100
Study: 29735964

Group type: EXPERIMENTAL
Intervention: Thunder-fire moxibustion therapy combined with calcium carbonate D3
Number of subjects: 63

Group type: COMPARATOR
Intervention: Calcium carbonate D3 only (Control)
Number of subjects: 63
Study: 27031702

Group type: EXPERIMENTAL
Intervention: RSV illness episodes during pregnancy
Number of subjects: 3693

Group type: COMPARATOR
Intervention: Women without RSV during pregnancy
Number of subjects: 3693

Group type: EXPERIMENTAL
Intervention: Postpartum RSV infection in mothers
Number of subjects: 3693
Study: 25112865

Group type: EXPERIMENTAL
Intervention: Deferiprone 20mg/kg/day
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Deferiprone 40mg/kg/day
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Deferiprone 60mg/kg/day
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Deferiprone 20mg/kg/day (subgroup analysis)
Number of subjects: 72
Study: 22747998

Group type: EXPERIMENTAL
Intervention: Intervention teams with priority flags for intensification added to the registry database.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control teams using the same database without the new information.
Number of subjects: 0
Study: 20825758

Group type: COMPARATOR
Intervention: Bipolar TURP
Number of subjects: 2245

Group type: COMPARATOR
Intervention: Bipolar TUVP
Number of subjects: 2245

Group type: COMPARATOR
Intervention: HoLEP
Number of subjects: 2245

Group type: COMPARATOR
Intervention: KTP laser vaporisation
Number of subjects: 2245
Study: 17609305

Group type: EXPERIMENTAL
Intervention: Ablative target-absorbed dose of 200 Gy (n = 78)
Number of subjects: 177

Group type: COMPARATOR
Intervention: Nonablative doses of 100 or 120 Gy (n = 99)
Number of subjects: 177
Study: 15640479

Group type: EXPERIMENTAL
Intervention: Soy protein containing 99 mg isoflavones/d
Number of subjects: 202

Group type: COMPARATOR
Intervention: Milk protein (placebo)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Soy protein containing 99 mg isoflavones/d (in equol producers)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Soy protein containing 99 mg isoflavones/d (in equol nonproducers)
Number of subjects: 202
Study: 11906798

Group type: EXPERIMENTAL
Intervention: 4 mg/day buprenorphine
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: 2 mg/day buprenorphine
Number of subjects: 330

Group type: COMPARATOR
Intervention: 1 mg/day buprenorphine
Number of subjects: 330
Study: 9950598

Group type: EXPERIMENTAL
Intervention: 2% cyclosporin A (CsA) drops for 3 months
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo drops for 3 months
Number of subjects: 8
Study: 8789590

Group type: EXPERIMENTAL
Intervention: Pizotifen (1 mg orally, administered 5 hours before exercise)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Pizotifen
Number of subjects: 8
Study: 2105371

Group type: EXPERIMENTAL
Intervention: Genuine acupuncture
Number of subjects: 49

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Both groups (Genuine and Sham)
Number of subjects: 49
Study: 41413

Group type: EXPERIMENTAL
Intervention: alpha-methyl-p-tyrosine (AMPT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: haloperidol
Number of subjects: 0

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0